Breast Cancer Clinical Trials & Research at Providence Medical Group

In the U.S., breast cancer is the second most common cancer in women after skin cancer. It can occur in both men and women. The most common type of breast cancer is ductal carcinoma, which begins in the cells of the ducts. Breast cancer can also begin in the cells of the lobules and in other tissues in the breast. Invasive breast cancer is breast cancer that has spread from where it began in the ducts or lobules to surrounding tissue.

Providence Medical Group is currently enrolling patients for the following breast cancer clinical trials:

Regional Radiotherapy in Biomarker Low-Risk Node Positive and T3N0 Breast Cancer (MA.39 TAILOR RT)

Treatment agent: Radiotherapy
Physician: Michael N. Corradetti, MD
Study Coordinator: Beatrice Becker // beatrice.becker@providence.org // 707-932-5164
Study Resources: https://clinicaltrials.gov/study/NCT03488693
Sponsor: National Cancer Institute (NCI) / Canadian Cancer Trials Group
Location: Providence Queen of the Valley Medical Center, Napa, CA

Sermonix SMX-22-002 ELAINE 3

Treatment agent: Lasofoxifene + abemaciclib vs fulvestrant + abemaciclib
Physician: Jarrod Holmes, MD
Study Coordinator: Camille Shaffer // camille.shaffer@stjoe.org // 707-521-3830
Study Resources: Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation - Full Text View - ClinicalTrials.gov
Sponsor: Sermonix Pharmaceuticals Inc.
Location: Providence Cancer Center, Santa Rosa, CA

Study for participants with Stave IV advanced/ metastatic Hormone Receptor positive, HER2 negative breast cancer (Capitello 292)

Treatment agent: Capiversitib + CDK4/6 inhibitor + Fulvestrant
Physician: Dr Jarrod Holmes
Study Coordinator: Melissa Ulrich // melissa.ulrich@providence.org // 707-521-3830 (Santa Rosa) or Aiah Ferrer // aiah.ferrer@providence.org // 707-932-5164 (Napa)
Study Resources: Study Details | Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292) | ClinicalTrials.gov
Sponsor: Capitello
Location: Providence Cancer Center, Santa Rosa, CA

Phase III Trial of Neoadjuvant Durvalumab (NSC 778709) plus Chemotherapy versus Chemotherapy Alone for Adults with MammaPrint Ultrahigh (MP2) Hormone Receptor (HR) Positive / Human Epidermal Growth Factor Receptor (HER2) Negative Stage II-III Breast Cancer

Treatment agent: Durvalumab plus SoC chemo vs. SoC chemo alone
Physician: Ian Anderson, MD
Study Coordinator: Camille Shaffer // camille.shaffer@stjoe.org // 707-521-3830
Study Resources: Study Details | Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer | ClinicalTrials.gov
Sponsor: National Cancer Institute (NCI)
Location: Providence Cancer Center, Santa Rosa, CA

S2212, SHORTER ANTHRACYCLINE-FREE CHEMO IMMUNOTHERAPY ADAPTED TO PATHOLOGICAL RESPONSE IN EARLY TRIPLE NEGATIVE BREAST CANCER (SCARLET), A RANDOMIZED PHASE III STUDY

Treatment agent: SOC 6 cycles of Chemo/immunotherapy (Carboplatin/Docetaxel/ Pembro) VS Chemo/immunotherapy with pembro 8 cycles + 4 cycles of carbo/paclitaxel + 4 cycles of doxorubicin/cyclophosphamide
Physician: Dr Daniel Paul Mirda, MD | Medical Oncology in Napa | Providence Medical Group Sonoma
Study Coordinator: Beatrice Becker // beatrice.becker@providence.org // 707-932-5164
Study Resources: Study Details | Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer | ClinicalTrials.gov
Sponsor: SWOG Cancer Research Network
Location: Providence Queen of the Valley Medical Center, Napa, CA

(HEAL-ABC): HARNESSING E-MINDFULNESS APPROACHES FOR LIVING-AFTER BREAST CANCER

Treatment agent: N/A
Physician: Sara A. Keck, MD | Santa Rosa, CA
Study Coordinator: Kim Young// Kimberly.Young@stjoe.org // 707-521-3830
Study Resources: Study Details | NCT06748222 | E-Mindfulness Approaches for Living After Breast Cancer | ClinicalTrials.gov
Sponsor: NRG Oncology
Location: Providence Cancer Center, Santa Rosa, CA

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of LY4064809 Combined with a CDK4/6 Inhibitor and Endocrine Therapy in Adults with HR+, HER2- Advanced Breast Cancer with a PIK3CA Mutation Who Received No Prior Treatment for Advanced Breast Cancer (PIKALO-2)

Treatment agent: LY4064809
Physician: Ian Anderson, MD
Study Coordinator: Davina Montelongo // Davina.Montelongo@providence.org // 707-521-3830
Study Resources: Study Details | NCT07174336 | A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA) | ClinicalTrials.gov
Sponsor: Eli Lilly and Company
Location: Providence Cancer Center, Santa Rosa, CA

A Phase 3, Randomized, Open-label, Study to Compare the Efficacy and Safety of Adjuvant MK-2870 in Combination with Pembrolizumab (MK-3475) Versus Treatment of Physician’s Choice (TPC) in Participants With Triple-Negative Breast Cancer (TNBC) Who Received Neoadjuvant Therapy and Did Not Achieve a Pathological Complete Response (pCR) at Surgery

Treatment agent: MK-2870 (ADC- TROP2) + pembro vs pembro or pembro + capecitabine
Physician: Ian Anderson, MD
Study Coordinator: Sam Hansen // Samantha.Hansen@stjoe.org // 707-521-3830
Study Resources: Study Details | NCT06393374 | Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012) | ClinicalTrials.gov
Sponsor: Merck Sharp & Dohme LLC
Location: Providence Cancer Center, Santa Rosa, CA